ClinicalTrials.gg
RecruitingNCT05865470SAGEUpdated Jan 7, 2026

Age-dependent Effects of Smoked and Oral Delta-9-THC

A Phase 1 interventional study of Cannabis and Dronabinol in Pain, Abuse, Drug and Intoxication; Cannabinoids, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by University of California, Los Angeles · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing cannabis sativa subsp. indica TOP in Pain — 2 open to participants now, 5 under way, none of them phase 3. cannabis sativa subsp. indica TOP · Pain.

Planned enrollment
2nd of 12
103 · median 31
Started
2025
with 1 other
Phase 1
7 of 12
2 open now
Registered
10th of 12
by date
Lead sponsor
4 of 12
University of California, Los Angeles

Among the 12 studies testing cannabis sativa subsp. indica TOP in Pain, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 1, and was the 10th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

2 of the 12 studies testing cannabis sativa subsp. indica TOP in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About cannabis sativa subsp. indica TOP

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing cannabis sativa subsp. indica TOP in Pain, or all of them as a file.
02

Study summary

This study will assess the age-dependent effects of smoked and oral THC on abuse liability, intoxication, analgesia and impairment as a function of age.

Read the detailed description

The overall objective of this placebo-controlled, outpatient study is to compare the dose-dependent effects of smoked and oral THC on analgesia and endpoints directly related to adverse consequences of use including abuse liability, intoxication, and impairment as a function of age and sex.

03

Conditions studied

  • Pain
  • Abuse, Drug
  • Intoxication; Cannabinoids

Keywords

  • Pain
  • Cannabis
  • Delta-9-THC
  • Age
  • Sex
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant female aged 18-65 years according to the below criteria: EMERGING ADULTS: 18-25 years of age (+/- one year) MIDDLE-AGED ADULTS: 35-45 years of age (+/- one year) LATE MIDDLE-AGED ADULTS: 55-65 years of age (+/- one year)
  • Report weekly-monthly use of cannabis (with primary mode of use via inhalation) over the past 6 months prior to screening
  • Not currently seeking treatment for their cannabis use
  • No reported adverse effects with cannabis use
  • Have a from 18.5 - 34kg/m2
  • Able to perform all study procedures
  • FEMALES: Currently practicing an effective form of if pre-menopausal

Exclusion criteria

Exclusion Criteria:

  • Meeting (Diagnostic and Statistical Manual of Mental Disorders-5) criteria for any substance use disorder other than nicotine and mild cannabis use disorder
  • Report using other illicit drugs in the prior 4 weeks
  • Evidence of severe psychiatric illness (e.g. mood disorder with functional impairment or suicide risk, schizophrenia) or medical condition (i.e., hypertension) judged by the study physician (and PI to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide .
  • Current predominant licit use of medical cannabis
  • Current use of prescription or regular use of over the counter medications (with the exception of hormonal and hormone replacement therapy). Current use of herbal supplements that may affect study outcomes or interact with study drug (i.e., St Johns wort, kava, L-tryptophan, melatonin)
  • If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures
  • Current pain
  • Pregnancy is exclusionary due to the possible effects of the study medication on fetal development
  • History of an allergic reaction or adverse reaction to cannabis is exclusionary.
  • Currently enrolled in another research protocol
  • Not using a contraceptive method (hormonal or barrier methods)
  • The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.
  • Intolerance to lactose and sesame (ingredients in the oral THC preparation)
  • Insensitivity to the Cold Pressor Test
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
103 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Comparator: Placebo

    Smoked Cannabis (0 mg THC) Oral placebo (0 mg THC)

    Drug: Smoked Placebo · Drug: Oral Placebo

  • Experimental
    Experimental: Low strength cannabis

    Smoked Cannabis (10 mg THC) Oral placebo (0 mg THC)

    Drug: Cannabis · Drug: Oral Placebo

  • Experimental
    Experimental: Higher strength cannabis

    Smoked Cannabis (20 mg THC) Oral placebo (0 mg THC)

    Drug: Cannabis · Drug: Oral Placebo

  • Experimental
    Experimental: Low strength oral THC

    Smoked Cannabis (0 mg THC) Oral THC (10 mg THC)

    Drug: Dronabinol · Drug: Smoked Placebo

  • Experimental
    Experimental: Higher strength oral THC

    Smoked Cannabis (0 mg THC) Oral THC (20 mg THC)

    Drug: Dronabinol · Drug: Smoked Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Subject-rated drug effects

    Average and peak subjective ratings of drug effects associated with abuse liability and intoxication as measured using visual analogue scales (VAS; 1-100mm).

    Time frame: 6 hours

  2. Analgesia as measured using the Cold Pressor Test

    Peak and average pain threshold and tolerance assessed using the Cold Pressor Test

    Time frame: 6 hours

  3. Impairment

    The primary outcome measure for performance will be the peak difference from baseline scores of the Global Impairment Score

    Time frame: 6 hours

  4. Pharmacokinetics of THC and metabolites

    Plasma levels of THC, 11-OH-THC, and THCCOOH

    Time frame: 6 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2028, 41 months after the start.

Of 118 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's planned 41 months is above that.

Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
May 18, 2023
StartActual
Apr 30, 2025
Primary completionEst.
Oct 15, 2028
CompletionEst.
Oct 15, 2029
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05865470
Responsible party
Ziva D. Cooper, PhD (Professor / Director, University of California, Los Angeles) — Principal investigator
First posted
May 18, 2023
Start date
Apr 30, 2025
Primary completion
Oct 15, 2028 (estimated)
Completion
Oct 15, 2029 (estimated)
Last update
Jan 7, 2026

Study contacts

Ziva D Cooper, PhD
Contact
zcooper@mednet.ucla.edu
310-983-3417
Vincent Acebo
Contact
vacebo@mednet.ucla.edu
310-983-3417
Ziva Cooper, PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cannabis sativa subsp. indica TOP · Dronabinol

Start the discussion